DTU
DTU

Targeting Iatrogenic Cushing's Syndrome with 11β-hydroxysteroid dehydrogenase type 1 Inhibition (TICSI)

News achive

Years :
Search news :

2023

Can the undesirable effects of steroid therapy be mitigated?

13-Mar-2023
News Image

Glucocorticoid induced hyperglycaemia and the development of type 2 diabetes mellitus are major downsides to the use of steroids for the treatment of acute and chronic inflammatory diseases. In a randomised controlled trial Professor Tomlinson and colleagues working with Professor Holman and the Diabetes Trials Unit have investigated whether AZD4017, an 11ß-HSD1 inhibitor, can attenuate glucocorticoid-associated side effects on blood pressure, glycaemia, bone, and lipid metabolism, assessed after 7 days therapy in healthy men....

[Read more...]

2019

TICSI completes recruitment

14-Mar-2019

The trial Targeting Iatrogenic Cushing's Syndrome with 11ß-hydroxysteroid dehydrogenase type 1 Inhibition (TICSI) met its recruitment target by enrolling 32 participants since June 2017. The last study visit took place on 27th February 2019....

[Read more...]

2017

First patient randomised

06-Jun-2017

The first patient has been randomised into the TICSI trial.